Cagrilintide for people with obesity who could not tolerate GLP-1 medicines
Tests cagrilintide against placebo in adults with obesity who stopped GLP-1 medicines.
Plain-language title generated from the registry record
Registry title: Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Key facts
- Where
- Amarillo, Austin, Bristol, Conyers, Fleming Island, Jacksonville, Monroe, North Charleston, Pembroke Pines, Statesville, Walnut Creek, Weston, and Wilmington, United StatesSee the 13 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who stopped GLP-1-RA medicines because of stomach and gut side effects. It compares Cagrilintide with placebo.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Body mass index (BMI) of 30.0 kg/m^2 or more.
- Earlier treatment
- Must have taken GLP-1-RA medicines and stopped mainly because of gastrointestinal side effects. Restarting GLP-1-RA treatment must not be possible, based on medical history and the investigator's judgement. No GLP-1-RA treatment in the 8 weeks before screening.
- Biomarker or test result
- HbA1c below 6.5 percent (48 mmol/mol) at screening.
Main reasons for not taking part
- Pregnant, breast-feeding, planning pregnancy, or able to have children and not using highly effective contraception
- History of type 1 or type 2 diabetes
- Medicine for diabetes or pre-diabetes in the 90 days before screening
- Medicine for weight management in the 8 weeks before screening
- GLP-1-RA medicine for any reason in the 8 weeks before screening
Read by machine on 9 November 2026.
Where in United States
- Amarillo Medical SpecialistsAmarillo, United StatesTaking people
- Elligo Clin Res CentreAustin, United StatesTaking people
- Holston Medical Group_BristolBristol, United StatesTaking people
- Hope Clin Res & WellnessConyers, United StatesNot yet recruiting
- Northeast Research InstituteFleming Island, United StatesTaking people
- Jacksonville Ctr for Clin ResJacksonville, United StatesTaking people
- Monroe Biomedical Research, LLCMonroe, United StatesTaking people
- Coastal Carolina Research CtrNorth Charleston, United StatesNot yet recruiting
- Center for Diab,Obes & MetabPembroke Pines, United StatesTaking people
- PHC AccelacareStatesville, United StatesNot yet recruiting
- Diablo Clinical Research, Inc.Walnut Creek, United StatesTaking people
- Encore Medical Research of WestonWeston, United StatesTaking people
- AccellacareWilmington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07607587
- Record updated
- 19 October 2026
- Original description
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.Read full original descriptionShow less
Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Inclusion: Male or female (sex at birth); Age 18 years or above at the time of signing the informed consent; History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation; Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement; Body mass index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg/m\^2).
Exclusion: Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening; Treatment with any medication prescribed for the indication of weight management within 8 weeks before screening; History of type 1 or type 2 diabetes; Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening; Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening; Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods.